Showing results (591-600 of 709) with videos related to

Sort By:
Pageof 71
Annals of Hepatology|April 23, 2022
Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in GermanyWolfgang Maximilian Kremer, Simon Johannes Gairing, Leonard Kaps, et al.
Transplantation|December 23, 2004
Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusionsJürgen Kuball, Matthias Theobald, Edite Antunes Ferreira, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 17, 2007
Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantationTim Zimmermann, Wulf O Böcher, Stefan Biesterfeld, et al.
The Journal of Experimental Medicine|October 10, 2007
Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLDNadine Hövelmeyer, F Thomas Wunderlich, Ramin Massoumi, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2019
Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise programYvonne Huber, Daniel Pfirrmann, Ines Gebhardt, et al.
Journal of Clinical Medicine|February 12, 2021
No Evidence for Classic Thrombotic Microangiopathy in COVID-19Tanja Falter, Heidi Rossmann, Philipp Menge, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2006
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitisChristoph Becker, Heike Dornhoff, Clemens Neufert, et al.
JHEP Reports : Innovation in Hepatology|April 2, 2025
QuickStroop for screening for minimal hepatic encephalopathy in patients with cirrhosisChristian Labenz, Simon J Gairing, Leonard Kaps, et al.
Journal of Hepatology|April 18, 2025
Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensusPaolo Angeli, Christian Labenz, Salvatore Piano, et al.
Plos One|April 1, 2021
Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive careL Kaps, C J Ahlbrand, R Gadban, et al.
Pageof 71